The National Institute for Health and Care Excellence (NICE) has made olaparib (Lynparza), a targeted cancer drug, more widely available for people with ovarian cancer on the NHS in England. Trial results have shown that olaparib, which stops cancer cells repairing damage to their DNA, can give patients more time before their cancer gets significantly bigger. The drug will be used to help prolong the effects of treatment for patients whose disease has come back and whose cancer tests positive for a faulty version of the BRCA gene. The decision covers people whose cancer has responded to second or later lines of platinum-based chemotherapy.
To learn more, see original article at: https://www.cancerresearchuk.org/about-us/cancer-news/news-report/2019-12-11-targeted-ovarian-cancer-drug-made-available-to-more-people-on-nhs-in-england
